IMBRUVICA follow-up data suggest long-term benefits for chronic lymphocytic leukaemia patients

AbbVie has announced new three-year follow-up data from the RESONATE™-2 study, which found that previously-untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients reported sustained improvements in measures of well-being with IMBRUVICA® (ibrutinib) versus chemotherapy with chlorambucil.

These new data provide the longest quality of life follow up for ibrutinib to date using patient-reported outcomes (PRO). Patients reported their quality of life outcomes for fatigue, mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

At 30 months, ibrutinib was also associated with a greater progression-free survival (PFS) rate of 85% versus chlorambucil, which had a PFS rate of 28%.

The new RESONATE-2 data was presented at the 59th American Society of Hematology Annual Meeting and Exposition on December 9 in Atlanta (abstract #1746).

IMBRUVICA is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor jointly developed and commercialised by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech.

CLL is the most common form of leukaemia in adults and is a type of cancer that can form from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes). While these cancer cells start in the bone marrow, they then later spread into the blood. The prevalence of CLL is approximately 115,000 patients in the U.S. with approximately 19,000 newly diagnosed patients every year

Dr Danelle James, Head of Clinical Science, Pharmacyclics LLC, said: “For patients with chronic lymphocytic leukaemia, a disease that affects primarily older patients, quality of life is an important consideration that should be factored into treatment choices initially and throughout long-term use.”